Seroquel XR in Schizophrenia Relapse Prevention

AstraZeneca1,600 enrolled

Overview

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Study Type

OBSERVATIONAL

Enrollment

1,600

Conditions

Schizophrenia Relapse Prevention

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month Exclusion Criteria: * Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Locations (48)

Outcomes

Primary Outcomes

Rate of patients remained relapse free after 6 months of treatment

Secondary Outcomes

Adherence rate of patients

Quality of Life (QoL )

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Baja, Hungary

Research Site

Barcs, Hungary

Research Site

Budapest, Hungary

Research Site

Cegléd, Hungary

Research Site

Debrecen, Hungary

Research Site

Dombóvár, Hungary

Research Site

Dunaújváros, Hungary

Research Site

Eger, Hungary

Research Site

Egerszalók, Hungary

Research Site

Emőd, Hungary

...and 38 more locations